Nano-X Imaging Ltd. — Form 6-K Summary
Business Context and Reporting Period
Nano-X Imaging Ltd., an Israel-based medical-imaging company, filed a Form 6-K covering April 2024. The filing reports the Company’s April 1, 2024 press release, which is incorporated by reference. The filing does not include the full press release or sufficient operating data to summarize the Company’s business performance for the period.
Financial Metrics
The filing text does not provide clear values for revenue, net income or loss, cash flow, margins, debt, liquidity, or other operating metrics. It states that the attached press release contains GAAP and non-GAAP financial measures, with certain legal and related expenses excluded from non-GAAP measures.
Material Changes and Unusual Items
- The Company and its directors and officers settled consolidated securities class actions, including the White Action and McLaughlin Action, for $8 million under a June 2023 settlement agreement.
- In December 2023, the Company deposited $5 million and its directors-and-officers insurance carrier deposited $3 million into a trust account for the settlement. Accordingly, the Company reported no settlement accrual as of December 31, 2023.
- The settlement remained subject to court approval and other conditions. A final approval hearing occurred on February 15, 2024, and the parties submitted updated settlement-claims information on February 29, 2024.
- The Company paid a $650,000 civil penalty to settle an SEC enforcement matter concerning disclosures about Nanox.ARC prototype development costs and estimated scaled assembly costs. The Company was permanently enjoined from violating specified provisions of the Securities Act and Exchange Act.
Legal Matters, Risks, and Contingencies
- A claimant is seeking approximately $1.26 million in alleged unpaid consulting fees and approximately $25 million related to claimed entitlement to securities of Nanox Imaging PLC, a separate Gibraltar entity. The Company denies the claims and states that it was not a party to the consulting agreement.
- A related claim was filed in Israel on or about December 21, 2023, against the Company, the Gibraltar entity, and the late former chairman Ran Poliakine. The Company states that the allegations were previously dismissed by a U.S. court, denies liability, and intends to defend the matter vigorously.
- The SEC settlement and shareholder litigation may affect reported results and the interpretation of non-GAAP measures, although the filing does not provide a complete quantified reconciliation.
Key Facts for Investors to Verify
- Review Exhibit 99.1 for the omitted GAAP financial statements, non-GAAP reconciliations, revenue, losses, cash position, liquidity, and outlook.
- Confirm the final court approval and payment status of the $8 million shareholder settlement.
- Assess the potential exposure from the Israeli claim and the separate Gibraltar-entity consulting and securities allegations.
- Consider the implications of the SEC injunction and $650,000 civil penalty for disclosure controls, regulatory compliance, and future reporting.
- Verify any management guidance or operating targets in the April 1 press release, which are not included in the filing text provided.